Skip to main content

Peer Review reports

From: Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study

Original Submission
29 Apr 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
11 Jun 2022 Reviewed Reviewer Report
12 Jun 2022 Reviewed Reviewer Report
5 Jul 2022 Author responded Author comments - Marina Elena Cazzaniga
Resubmission - Version 5
5 Jul 2022 Submitted Manuscript version 5
8 Jul 2022 Author responded Author comments - Marina Elena Cazzaniga
Resubmission - Version 6
8 Jul 2022 Submitted Manuscript version 6
12 Jul 2022 Author responded Author comments - Marina Elena Cazzaniga
Resubmission - Version 7
12 Jul 2022 Submitted Manuscript version 7
12 Jul 2022 Author responded Author comments - Marina Elena Cazzaniga
Resubmission - Version 8
12 Jul 2022 Submitted Manuscript version 8
15 Jul 2022 Author responded Author comments - Marina Elena Cazzaniga
Resubmission - Version 9
15 Jul 2022 Submitted Manuscript version 9
31 Jul 2022 Reviewed Reviewer Report
1 Aug 2022 Reviewed Reviewer Report
Resubmission - Version 10
Submitted Manuscript version 10
Publishing
9 Aug 2022 Editorially accepted
6 Sep 2022 Article published 10.1186/s12885-022-10031-6

You can find further information about peer review here.

Back to article page